medigraphic.com
ISSN 1561-2988 (Impreso)

2022, Número 2

<< Anterior Siguiente >>

Rev Cubana Farm 2022; 55 (2)


Suplementos probióticos en enfermedades del entorno gastrointestinal por alteración de la microbiota tras la antibioterapia

Tapia VE, Trelis VM, Gozalbo MM

Idioma: Español
Referencias bibliográficas: 50
Paginas: 1-17
Archivo PDF: 692.15 Kb.


RESUMEN

Introducción: La microbiota puede verse alterada debido al uso de antibióticos para el tratamiento de enfermedades del entorno gastrointestinal. La suplementación con probióticos podría emplearse terapéuticamente para regular o evitar esta disbiosis.
Objetivo: Analizar la información relevante sobre el uso de probióticos como coadyuvante en el tratamiento con antibióticos en enfermedades del entorno gastrointestinal que pueden alterar su microbiota.
Métodos: Revisión bibliográfica en bases de datos científicas de artículos relacionados con el tema y publicados entre enero de 2010 a junio de 2020. Se encontraron 132 artículos, 43 se incluyeron tras cumplir los criterios de selección, relevancia científica y metodológica.
Conclusiones: El uso de ciertos probióticos está recomendado para tratar la diarrea asociada a antibióticos, infección por Clostridium difficile y prevención de su diarrea asociada e infección por Helicobater pylori, pero no se recomienda para la inflamación del reservorio íleoanal. La recomendación probiótica debe recetarse por un profesional sanitario cualificado. Aún se requieren estudios con mejores diseños metodológicos para lograr formulaciones enfocadas en la terapia personalizada.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Salvo-Romero Eloísa, Alonso-Cotoner Carmen, Pardo-Camacho Cristina, Casado-BedmarMaite, Vicario María. The intestinal barrier function and its involvement in digestive disease.Rev. esp. enferm. dig. 2015;107(11):686-96. DOI: 10.17235/reed.2015.3846/2015

  2. Sanz Y, De Palma G. Gut microbiota and probiotics in modulation of epithelium and gutassociatedlymphoid tissue function. Int Rev Immunol. 2009;28(6):397-413. DOI:10.3109/08830180903215613

  3. Castañeda Guillot C. Microbiota intestinal, probióticos y prebióticos. Enferm Inv.2017;2(4):156-60. DOI: 10.29033/ei.v2n4.2017.07

  4. Etxeberria U, Milagro FI, González‑Navarro CJ, Martínez JA. Papel en la obesidad de lamicrobiota intestinal. Anales de la Real Academia Nacional de Farmacia. 2016 [acceso15/02/2020];82:234-59. Disponible en:https://dialnet.unirioja.es/servlet/articulo?codigo=6658290

  5. Halloran K, Underwood MA. Probiotic mechanisms of action. Early Hum Dev.2019;135:58-65. DOI: 10.1016/j.earlhumdev.2019.05.010

  6. Ferrer M, Méndez-García C, Rojo D, Barbas C, Moya A. Antibiotic use and microbiomefunction. Biochem Pharmacol. 2017;134:114-26. DOI: 10.1016/j.bcp.2016.09.007

  7. Álvarez Calatayud G, Marcos A, Margolles A. Probióticos, prebióticos y salud: EvidenciaCientífica. Ergon; 2016 [acceso 20/03/2020]. Disponible en: https://ergon.es/wpcontent/uploads/2016/07/ergon_primeras_Manual_SEPyP.pdf

  8. Hungin APS, Mitchell CR, Whorwell P, Mulligan C, Cole O, Agréus L, et al. Systematicreview: probiotics in the management of lower gastrointestinal symptoms - an updatedevidence-based international consensus. Aliment Pharmacol Ther. 2018;47(8):1054-70. DOI:10.1111/apt.14539

  9. Jafarnejad S, Shab-Bidar S, Speakman JR, Parastui K, Daneshi-Maskooni M, Djafarian K.Probiotics Reduce the Risk of Antibiotic-Associated Diarrhea in Adults (18-64 Years) butNot the Elderly (> 65 Years): A Meta-Analysis. Nutr Clin Pract. 2016;31(4):502-13. DOI: 10.1177/0884533616639399

  10. García Trallero O, Herrera Serrano L, Bibián Inglés M, Roche Vallés D, Rodríguez AM.Effect of the administration of a probiotic with a combination of Lactobacillus andBifidobacterium strains on antibiotic-associated diarrhea. Rev Esp Quimioter. 2019 [acceso17/02/2020];32(3):268-72. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609938/

  11. Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibioticassociateddiarrhea and Clostridium difficile infection among hospitalized patients:systematic review and meta-analysis. Open Med. 2013 [acceso 20/03/2020];7(2):e56-67.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863752/

  12. Szajewska H, Kołodziej M. Systematic review with meta-analysis: Lactobacillusrhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults.Aliment Pharmacol Ther. 2015;42(10):1149-57. DOI: 10.1111/apt.13404

  13. Szajewska H, Kołodziej M. Systematic review with meta-analysis: Saccharomycesboulardii in the prevention of antibiotic-associated diarrhea. Aliment Pharmacol Ther.2015;42(7):793-801. DOI: 10.1111/apt.13344

  14. Koretz RL. Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?. Am JGastroenterol. 2018;113(8):1125-36. DOI: 10.1038/s41395-018-0138-0

  15. Mantegazza C, Molinari P, D’Auria E, Sonnino M, Morelli L, Zuccotti GV. Probioticsand antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillusrhamnosus GG during and after antibiotic treatment. Pharmacol Res. 2018;128:63-72. DOI:10.1016/j.phrs.2017.08.001

  16. Xu H-B, Jiang R-H, Sheng H-B. Meta-analysis of the effects of Bifidobacteriumpreparations for the prevention and treatment of pediatric antibiotic-associated diarrhea inChina. Complement Ther Med. 2017;33:105-13. DOI: 10.1016/j.ctim.2017.07.001

  17. Agamennone V, Krul CAM, Rijkers G, Kort R. A practical guide for probiotics appliedto the case of antibiotic-associated diarrhea in The Netherlands. BMC Gastroenterol.2018;18(1):103. DOI: 10.1186/s12876-018-0831-x

  18. Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Choosing an appropriate probioticproduct for your patient: An evidence-based practical guide. PLoS One.2018;13(12):e0209205. DOI: 10.1371/journal.pone.0209205

  19. Guarino A, Ashkenazi S, Gendrel D, Lo Vecchio A, Shamir R, Szajewska H. EuropeanSociety for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society forPediatric Infectious Diseases evidence-based guidelines for the management of acutegastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr. 2014;59(1):132-52. DOI: 10.1097/MPG.0000000000000375

  20. Rodríguez-Varón A, Muñoz OM, Pulido-Arenas J, Amado SB, Tobón-Trujillo M.Diarrea asociada a antibióticos: características clínicas y presencia de Clostridium difficile.Rev Gastroenterol Mex. 2017;82(2):129-33. DOI: 10.1016/j.rgmx.2016.10.003

  21. Goldenberg JZ, Ma SS, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, et al.Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults andchildren. Cochrane Database Syst Rev. 2013;(5):CD006095. DOI:10.1002/14651858.CD006095.pub3

  22. Goldenberg JZ, Yap C, Lytvyn L, Lo CK-F, Beardsley J, Mertz D, et al. Probiotics forthe prevention of Clostridium difficile-associated diarrhea in adults and children. CochraneDatabase Syst Rev. 2017;12(12):CD006095. DOI: 10.1002/14651858.CD006095.pub4

  23. McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adultantibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol.2016; 22(11):3078-104. DOI: 10.3748/wjg.v22.i11.3078

  24. Wilkins T, Sequoia J. Probiotics for Gastrointestinal Conditions: A Summary of theEvidence. Am Fam Physician. 2017 [acceso 08/02/2020];96(3):170-8. Disponible en:https://www.aafp.org/afp/2017/0801/p170.html

  25. Barker AK, Duster M, Valentine S, Hess T, Archbald-Pannone L, Guerrant R, et al. Arandomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO).J Antimicrob Chemother. 2017;72(11):3177-80. DOI: 10.1093/jac/dkx254

  26. Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, et al. Timely Use ofProbiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A SystematicReview With Meta-Regression Analysis. Gastroenterology. 2017;152(8):1889-1900.e9.DOI: 10.1053/j.gastro.2017.02.003

  27. McFarland LV, Ship N, Auclair J, Millette M. Primary prevention of Clostridium difficileinfections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L.rhamnosus strains: assessing the evidence. J Hosp Infect. 2018;99(4):443-52. DOI:10.1016/j.jhin.2018.04.017

  28. Carstensen JW, Chehri M, Schønning K, Rasmussen SC, Anhøj J, Godtfredsen NS, et al.Use of prophylactic Saccharomyces boulardii to prevent Clostridium difficile infection inhospitalized patients: a controlled prospective intervention study. Eur J Clin Microbiol InfectDis. 2018;37(8):1431-9. DOI: 10.1007/s10096-018-3267-x

  29. Shi X, Zhang J, Mo L, Shi J, Qin M, Huang X. Efficacy and safety of probiotics ineradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore).2019;98(15):e15180. DOI: 10.1097/MD.0000000000015180

  30. Chen L, Xu W, Lee A, He J, Huang B, Zheng W, et al. The impact of Helicobacter pyloriinfection, eradication therapy and probiotic supplementation on gut microenvironmenthomeostasis: An open-label, randomized clinical trial. EBioMedicine. 2018; 35:87-96. DOI:10.1016/j.ebiom.2018.08.028

  31. Pourmasoumi M, Najafgholizadeh A, Hadi A, Mansour-Ghanaei F, Joukar F. The effectof synbiotic in improving Helicobacter pylori eradication: A systematic review and metaanalysis.Complement. Ther. Med. 2019;43:36-43. DOI: 10.1016/j.ctim.2019.01.005

  32. Wang F, Feng J, Chen P, Liu X, Ma M, Zhou R, et al. Probiotics in Helicobacter pylorieradication therapy: Systematic review and network meta-analysis. Clin Res HepatolGastroenterol. 2017 Sep;41(4):466-475. DOI: 10.1016/j.clinre.2017.04.004

  33. Li BZ, Threapleton DE, Wang JY, Xu JM, Yuan JQ, Zhang Chao, et al. Comparativeeffectiveness and tolerance of treatments for Helicobacter pylori: systematic review andnetwork meta-analysis. BMJ 2015; 351:h4052. DOI: 10.1136/bmj.h4052

  34. Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in Helicobacter pylorieradication therapy: A systematic review and meta-analysis. World J Gastroenterol.2015;21(14): 4345-57. DOI: 10.3748/wjg.v21.i14.4345

  35. Yu M, Zhang R, Ni P, Chen S, Duan G. Efficacy of Lactobacillus-supplemented tripletherapy for H. pylori eradication: A meta-analysis of randomized controlled trials. PLoS One.2019;14(10):e0223309. DOI: 10.1371/journal.pone.0223309

  36. Fang H-R, Zhang G-Q, Cheng J-Y, Li Z-Y. Efficacy of Lactobacillus-supplemented tripletherapy for Helicobacter pylori infection in children: a meta-analysis of randomizedcontrolled trials. Eur J Pediatr. 2019;178(1):7-16. DOI: 10.1007/s00431-018-3282-z

  37. Feng P, Ye Z, Kakade A, Virk AK, Li X, Liu P. A Review on Gut Remediation of SelectedEnvironmental Contaminants: Possible Roles of Probiotics and Gut Microbiota. Nutrients.2018;11(1):22. DOI: 10.3390/nu11010022

  38. Poonyam P, Chotivitayatarakorn P, Vilaichone R-K. High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement forHelicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.Asian Pac J Cancer Prev. 2019;20(9):2859-64. DOI: 10.31557/APJCP.2019.20.9.2859

  39. McNicholl AG, Molina-Infante J, Lucendo AJ, Calleja JL, Pérez-Aisa Á, Modolell I, etal. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici forHelicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial.Helicobacter. 2018;23(5):e12529. DOI: 10.1111/hel.12529

  40. Seddik H, Boutallaka H, Elkoti I, Nejjari F, Berraida R, Berrag S, et al. Saccharomycesboulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: arandomized, open-label trial. Eur J Clin Pharmacol. 2019;75(5):639-45. DOI:10.1007/s00228-019-02625-0

  41. Zhou B-G, Chen L-X, Li B, Wan L-Y, Ai Y-W. Saccharomyces boulardii as an adjuvanttherapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trialsequential analysis. Helicobacter. 2019;24(5):e12651. DOI: 10.1111/hel.12651

  42. Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis:Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection.Aliment Pharmacol Ther. 2015;41(12):1237-45. DOI: 10.1111/apt.13214

  43. Nguyen N, Zhang B, Holubar SD, Pardi DS, Singh S. Treatment and prevention ofpouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane DatabaseSyst Rev. 2019;11(11):CD001176. DOI: 10.1002/14651858.CD001176.pub4

  44. Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS. Treatment and prevention ofpouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.2015;(11):CD001176. DOI: 10.1002/14651858.CD001176.pub2

  45. Assche G van, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, et al. Segundoconsenso europeo basado en evidencia sobre el diagnóstico y tratamiento de la colitis ulcerosacrónica idiopática. Parte 3: situaciones especiales (versión española). Rev. Gastroenterol.Méx. 2015;80(1):74-106. DOI: 10.1016/j.rgmx.2014.10.008

  46. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Societyof Gastroenterology consensus guidelines on the management of inflammatory bowel diseasein adults .Gut; 2019; 68(Suppl 3):s1–106. DOI: 10.1136/gutjnl-2019-318484

  47. Bengtsson J, Adlerberth I, Östblom A, Saksena P, Öresland T, Börjesson L. Effect ofprobiotics (Lactobacillus plantarum 299 plus Bifidobacterium Cure21) in patients with poorileal pouch function: a randomised controlled trial. Scand J Gastroenterol. 2016;51(9):1087–92. DOI:10.3109/00365521.2016.1161067

  48. Yasueda A, Mizushima T, Nezu R, Sumi R, Tanaka M, Nishimura J, et al. The effect ofClostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of themicrobiota profile in patients with ulcerative colitis. Surg Today. 2016;46(8):939-49. DOI:10.1007/s00595-015-1261-9

  49. Abraham B, Quigley EMM. Antibiotics and probiotics in inflammatory bowel disease:when to use them?. Frontline Gastroenterol. 2020;11(1):62-9. DOI: 10.1136/flgastro-2018-101057

  50. Tomasz B, Zoran S, Jarosław W, Ryszard M, Marcin G, Robert B. Long-term use ofprobiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence andseverity of pouchitis: a randomized prospective study. Biomed Res Int. 2014;2014:208064.DOI: 10.1155/2014/208064




2020     |     www.medigraphic.com